Hemogenyx Pharmaceuticals

1. 28 Sep 26
   Half-year Results

   Interim Results for the period ended 30 June 2026

   RNS 9792627 ↗
2. 03 Sep 26
   Exercise of Warrants and Issue of Equity

   Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 96,825 new ordinary shares in the Company (the "Warrant Shares").

   RNS 9752806 ↗
3. 11 Aug 26
   Collaboration with Cellin Technologies

   Hemogenyx Pharmaceuticals Signs Definitive Collaboration Agreement with Cellin Technologies for Manufacturing and Commercialization of HG-CT-1 CAR-T Therapy in Estonia

   RNS 9714349 ↗
4. 29 Jul 26
   Collaboration and Company Update

   Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research

   RNS 9692329 ↗
5. 30 Apr 26
   Final Results

   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2025.

   RNS 9547533 ↗
6. 28 Apr 26
   Institutional Fundraise

   Hemogenyx Secures £3,000,000 to accelerate its Phase 1 Clinical Trials and initiate early commercialization of HG-CT-1

   RNS 9540479 ↗
7. 14 Apr 26
   Annual IND Report with FDA

   Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML

   RNS 9518094 ↗
8. 31 Mar 26
   Tech Transfer Completion and Clinical Trial Update

   Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company focused on the development of innovative therapies for the treatment of blood diseases, is pleased to provide the following update on its HG-CT-1 CAR-T cell therapy program for...

   RNS 9501187 ↗
9. 23 Feb 26
   Exercise of Warrants and Issue of Equity

   Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 50,841 new ordinary shares in the Company (the "Warrant Shares").

   RNS 9441293 ↗
10. 22 Dec 25
    Update on Admission of Shares

    Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.

    RNS 9312170 ↗
11. 29 Oct 25
    Clinical Trial Update and Grant of Share Awards

    DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team

    RNS 9200443 ↗
12. 06 Oct 25
    Clearance to Initiate Pediatric Enrolment

    MD Anderson Clearance to Initiate Pediatric Enrolment in HG-CT-1 Clinical Trial

    RNS 9151440 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.